JP2021512896A5 - - Google Patents
Info
- Publication number
- JP2021512896A5 JP2021512896A5 JP2020542569A JP2020542569A JP2021512896A5 JP 2021512896 A5 JP2021512896 A5 JP 2021512896A5 JP 2020542569 A JP2020542569 A JP 2020542569A JP 2020542569 A JP2020542569 A JP 2020542569A JP 2021512896 A5 JP2021512896 A5 JP 2021512896A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- migalastat
- use according
- salt
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023192942A JP2024026080A (ja) | 2018-02-06 | 2023-11-13 | 古典型ファブリー病患者の治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862626992P | 2018-02-06 | 2018-02-06 | |
| US62/626,992 | 2018-02-06 | ||
| PCT/US2019/016853 WO2019157056A1 (en) | 2018-02-06 | 2019-02-06 | Treatment of patients with classic fabry disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023192942A Division JP2024026080A (ja) | 2018-02-06 | 2023-11-13 | 古典型ファブリー病患者の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021512896A JP2021512896A (ja) | 2021-05-20 |
| JP2021512896A5 true JP2021512896A5 (https=) | 2023-06-06 |
Family
ID=65494622
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542569A Withdrawn JP2021512896A (ja) | 2018-02-06 | 2019-02-06 | 古典型ファブリー病患者の治療 |
| JP2023192942A Pending JP2024026080A (ja) | 2018-02-06 | 2023-11-13 | 古典型ファブリー病患者の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023192942A Pending JP2024026080A (ja) | 2018-02-06 | 2023-11-13 | 古典型ファブリー病患者の治療 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20210038579A1 (https=) |
| EP (2) | EP3749308B1 (https=) |
| JP (2) | JP2021512896A (https=) |
| KR (1) | KR20200128675A (https=) |
| CN (1) | CN112203657A (https=) |
| AR (1) | AR114392A1 (https=) |
| AU (2) | AU2019217603A1 (https=) |
| DK (1) | DK3749308T3 (https=) |
| ES (1) | ES2969263T3 (https=) |
| FI (1) | FI3749308T3 (https=) |
| HR (1) | HRP20240025T1 (https=) |
| HU (1) | HUE064761T2 (https=) |
| LT (1) | LT3749308T (https=) |
| PL (1) | PL3749308T3 (https=) |
| PT (1) | PT3749308T (https=) |
| RS (1) | RS65103B1 (https=) |
| SI (1) | SI3749308T1 (https=) |
| SM (1) | SMT202400027T1 (https=) |
| TW (2) | TWI869336B (https=) |
| WO (1) | WO2019157056A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2533050T6 (pl) | 2006-05-16 | 2016-05-31 | Amicus Therapeutics Inc | Możliwości leczenia choroby Fabry'ego |
| EP2946785B1 (en) | 2008-02-12 | 2018-10-24 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| CA3224546C (en) | 2017-05-30 | 2026-02-24 | Amicus Therapeutics, Inc. | Use of migalastat in the treatment of fabry patients |
| KR20200128676A (ko) | 2018-02-06 | 2020-11-16 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도 |
| US12594268B2 (en) | 2018-08-20 | 2026-04-07 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
| KR20220044560A (ko) | 2019-08-07 | 2022-04-08 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법 |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| PL2533050T6 (pl) * | 2006-05-16 | 2016-05-31 | Amicus Therapeutics Inc | Możliwości leczenia choroby Fabry'ego |
| MX2009010557A (es) | 2007-03-30 | 2009-11-19 | Amicus Therapeutics Inc | Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas. |
| EP2946785B1 (en) | 2008-02-12 | 2018-10-24 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| KR20190087673A (ko) * | 2016-03-22 | 2019-07-24 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법 |
| TW202408513A (zh) * | 2016-07-19 | 2024-03-01 | 美商阿米庫斯醫療股份有限公司 | 治療ert初治的和已經歷ert的患者中之法布瑞氏症 |
| SG11202000423XA (en) * | 2017-07-19 | 2020-02-27 | Amicus Therapeutics Inc | Treatment of fabry disease in ert-naïve and ert-experienced patients |
-
2019
- 2019-02-06 PT PT197061823T patent/PT3749308T/pt unknown
- 2019-02-06 US US16/967,824 patent/US20210038579A1/en active Pending
- 2019-02-06 FI FIEP19706182.3T patent/FI3749308T3/fi active
- 2019-02-06 AU AU2019217603A patent/AU2019217603A1/en not_active Abandoned
- 2019-02-06 SI SI201930691T patent/SI3749308T1/sl unknown
- 2019-02-06 JP JP2020542569A patent/JP2021512896A/ja not_active Withdrawn
- 2019-02-06 DK DK19706182.3T patent/DK3749308T3/da active
- 2019-02-06 WO PCT/US2019/016853 patent/WO2019157056A1/en not_active Ceased
- 2019-02-06 HR HRP20240025TT patent/HRP20240025T1/hr unknown
- 2019-02-06 HU HUE19706182A patent/HUE064761T2/hu unknown
- 2019-02-06 PL PL19706182.3T patent/PL3749308T3/pl unknown
- 2019-02-06 KR KR1020207025688A patent/KR20200128675A/ko not_active Ceased
- 2019-02-06 AR ARP190100287A patent/AR114392A1/es unknown
- 2019-02-06 EP EP19706182.3A patent/EP3749308B1/en active Active
- 2019-02-06 SM SM20240027T patent/SMT202400027T1/it unknown
- 2019-02-06 ES ES19706182T patent/ES2969263T3/es active Active
- 2019-02-06 CN CN201980024335.8A patent/CN112203657A/zh active Pending
- 2019-02-06 RS RS20240081A patent/RS65103B1/sr unknown
- 2019-02-06 LT LTEPPCT/US2019/016853T patent/LT3749308T/lt unknown
- 2019-02-06 EP EP23200414.3A patent/EP4316589A3/en active Pending
- 2019-02-11 TW TW108104436A patent/TWI869336B/zh active
- 2019-02-11 TW TW113148020A patent/TW202537622A/zh unknown
-
2023
- 2023-11-13 JP JP2023192942A patent/JP2024026080A/ja active Pending
-
2025
- 2025-01-07 AU AU2025200074A patent/AU2025200074A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512896A5 (https=) | ||
| JP2020531550A5 (https=) | ||
| IL272893B1 (en) | Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease | |
| CA2966195C (en) | Oral adamantine in the treatment of gait disorders in multiple sclerosis patients | |
| EP2129400A2 (en) | Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders | |
| JP6511492B2 (ja) | 女性胃不全麻痺に関係する症状の処置 | |
| JP2015517994A (ja) | ハロフジノンの剤形およびその使用 | |
| Prommer | The role of fentanyl in cancer-related pain | |
| Plänitz | Comparison of moxonidine and clonidine HCl in treating patients with hypertension | |
| US20080311196A1 (en) | All Day Rhinitic Condition Treatment Regimen | |
| JP2005512946A5 (https=) | ||
| JP2013536206A5 (https=) | ||
| DINAI et al. | Bradycardia induced by interaction between quinidine and ophthalmic timolol | |
| Chervinsky et al. | Long-term cardiovascular safety of salmeterol powder pharmacotherapy in adolescent and adult patients with chronic persistent asthma: a randomized clinical trial | |
| JPS5823618A (ja) | 精神分裂症を治療する組成物 | |
| Adams et al. | Evaluation and pharmacologic approach to patients with resistant hypertension | |
| EP2727595B1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| US12303503B1 (en) | Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain | |
| US7608625B2 (en) | Method for treating bruxism and bruxism-related diseases | |
| EP3711759B1 (en) | Blend containing aripiprazole and a carbamate compound for prevention, mitigation, or treatment of schizophrenia | |
| Maesen et al. | Formoterol suspension aerosol: comparison with formoterol solution aerosol for 12 weeks in asthmatic patients | |
| Abbou | The efficacy and tolerance of indapamide in essential hypertension: a multi-centre study in 981 patients | |
| Ishikawa et al. | Elimination of unstable angina by diltiazem under temporary pacing | |
| Innes | Desloratadine-first clinical data in rhinitis revealed | |
| Chaplin et al. | Glycopyrronium (Seebri Breezhaler): once‐daily LAMA for COPD |